DT2216 vs Navitoclax
Written by Aaron CuhaReviewed Sep 2026
The short answer
The lab built fix for navitoclax's platelet problem. It hands the same target protein to a cell disposal system that platelets barely have. In its first human trial of 20 patients with solid tumours, one dose caused a problem bad enough to limit dosing: a severe drop in platelets that cleared within 48 hours.
- DT2216 people
- 20
- DT2216 nulls
- 0
- Navitoclax people
- 137
- Navitoclax nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 20 people given it
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 137 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
DT2216DT2216, VHL-recruiting PROTAC degrader of BCL-xL
Built to fix navitoclax's platelet problem. It hands the target protein to a cell tool that platelets barely have. In its first study, in 20 people with solid cancers, only one had a dose-limiting problem: a severe platelet drop that cleared within 48 hours.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Side by side, on the facts we can check
| What we compare | DT2216 | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Not approved. Still being tested as a cancer drug. The first early safety study in people is done. It set a dose for mid-stage studies of 0.4 mg/kg, given into a vein twice a week. No study for ageing or for clearing worn-out cells is registered. | Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov. |
| Half-life | Not reported | Not reported |
| Molecular weight | Not reported | Not reported |
| How it works | Shown in human cells and mice, with the platelet sparing now backed by the first study in people: DT2216 grabs BCL-xL and pulls in a cell tool called VHL. VHL tags BCL-xL so the cell destroys it. Platelets have very little VHL, so this barely happens in them. Worn-out cells that need BCL-xL die when it is gone. That is the clean-up idea, and it has been shown in mice, not in people. In the study in people, BCL-xL was destroyed in white blood cells at the top dose. | Shown in human cells and in mice: navitoclax sits in a pocket on BCL-2, BCL-xL and BCL-w. That frees up other proteins that tell the cell to die, so cells that lean on those three proteins die off. In mice, worn-out cells lean on them, which is why the drug hits those cells hardest. In people, platelets lean on the same protein, so their count drops. The cancer studies confirmed that. The clean-up effect seen in mice has never been shown in a person. |
| Studies in people | 4 | 4 |
| Evidence | Limited: 1 completed trial, 20 people given it | Moderate: 2 completed trials, 137 people given it |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between DT2216 and Navitoclax?
DT2216: Built to fix navitoclax's platelet problem. It hands the target protein to a cell tool that platelets barely have. In its first study, in 20 people with solid cancers, only one had a dose-limiting problem: a severe platelet drop that cleared within 48 hours. Navitoclax: The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Which has stronger research evidence, DT2216 or Navitoclax?
Each compound gets a band worked out from facts we counted, with the math shown. DT2216 is Limited (1 completed trial, 20 people given it). Navitoclax is Moderate (2 completed trials, 137 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are DT2216 and Navitoclax FDA-approved?
DT2216: Not approved. Still being tested as a cancer drug. The first early safety study in people is done. It set a dose for mid-stage studies of 0.4 mg/kg, given into a vein twice a week. No study for ageing or for clearing worn-out cells is registered.. Navitoclax: Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov..
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.